重组人血管内皮抑制素结合CT引导下经皮穿刺微波消融术治疗晚期NSCLC合并COPD的临床观察

发布时间：2018-02-26 18:35

  本文关键词： 重组人血管内皮抑制素 CT引导下经皮穿刺微波消融术 非小细胞肺癌 慢性阻塞性肺疾病 肺功能 生存质量　出处：《中国药房》2017年26期 　论文类型：期刊论文

【摘要】：目的:观察重组人血管内皮抑制素结合CT引导下经皮穿刺微波消融术治疗晚期非小细胞肺癌(NSCLC)合并慢性阻塞性肺疾病(COPD)的临床疗效及安全性。方法:选择2014年2月-2016年2月我院收治的80例晚期NSCLC合并COPD患者,按随机数字表法分为对照组和观察组,各40例。对照组患者给予CT引导下经皮穿刺微波消融术治疗;观察组患者在对照组基础上加用重组人血管内皮抑制素注射液7.5 mg/m2静脉滴注,4 h滴完,d1~14,连续治疗14 d后休息7 d再进行下一周期治疗。每个治疗周期为21 d,共治疗4个周期。比较两组患者的生存时间、临床疗效、治疗前后的卡氏(KPS)评分和肺功能指标,以及不良反应发生情况。结果:观察组患者的中位生存时间(19.8个月)明显长于对照组(15.2个月),总有效率(72.5%)明显高于对照组(55.0%),差异均有统计学意义(P0.05)。治疗前,两组患者的KPS评分、1 s用力呼气容量(FEV1)、FEV1/用力肺活量(FVC)和肺一氧化碳弥散量(DLCO)比较,差异均无统计学意义(P0.05);治疗后,两组患者的KPS评分和上述肺功能指标水平均较治疗前明显升高,且观察组均明显高于对照组,差异均有统计学意义(P0.05)。两组患者均未见Ⅳ级不良反应发生,各级别不良反应发生例数比较,差异均无统计学意义(P0.05)。结论:重组人血管内皮抑制素结合CT引导下经皮穿刺微波消融术治疗晚期NSCLC合并COPD的临床疗效较好、不良反应较轻,能明显改善患者的肺功能和生存质量。
[Abstract]:Objective: to observe the clinical efficacy and safety of recombinant human vascular endotheliostatin combined with CT guided percutaneous microwave ablation in the treatment of advanced non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD). From June to February 2016, 80 patients with advanced NSCLC complicated with COPD were treated in our hospital. The patients in the control group were divided into control group and observation group with 40 cases each. The patients in the control group were treated with CT guided percutaneous microwave ablation. The patients in the observation group were treated with recombinant human vascular endothelin injection of 7.5 mg/m2 intravenous drip for 4 h, followed by rest for 7 days after continuous treatment for 14 days and then the next cycle of treatment. Each treatment period was 21 days, and the treatment was cooperative. in the observation group, the patients in the observation group were treated with recombinant human vascular endotheliostatin injection for 4 hours after 4 hours of intravenous drip. Four cycles of treatment. The survival time of the two groups was compared. Clinical efficacy, KPS score and pulmonary function index before and after treatment, Results: the median survival time (19.8 months) in the observation group was significantly longer than that in the control group (15.2 months and the total effective rate was 72.5 months), which was significantly higher than that in the control group (55.0%, P 0.05). There was no significant difference in KPS score between the two groups (1 s forced expiratory volume, FEV1 / FEV1 / forced vital capacity) and lung carbon monoxide diffusion volume (DLCO) (P 0.05), but no significant difference was found between the two groups (P < 0.05), but no significant difference was found between the two groups (P < 0.01), but no significant difference was found between the two groups (P < 0.05). The KPS score and the pulmonary function index of the two groups were significantly higher than those of the control group, and the difference was statistically significant (P 0.05). No grade 鈪，

本文编号：1539189